Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.
Eissing T, Goulooze SC, van den Berg P, van Noort M, Ruppert M, Snelder N, Garmann D, Lippert J, Heinig R, Brinker M, Heerspink HJL. Eissing T, et al. Among authors: snelder n. Diabetes Obes Metab. 2024 Mar;26(3):924-936. doi: 10.1111/dom.15387. Epub 2023 Nov 30. Diabetes Obes Metab. 2024. PMID: 38037539 Clinical Trial.
Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.
Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, Garmann D, Ploeger B, Eissing T. Snelder N, et al. Clin Pharmacokinet. 2020 Mar;59(3):359-370. doi: 10.1007/s40262-019-00820-x. Clin Pharmacokinet. 2020. PMID: 31583611 Free PMC article. Clinical Trial.
Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease.
Hoefman S, Snelder N, van Noort M, Garcia-Hernandez A, Onkels H, Larsson TE, Bergmann KR. Hoefman S, et al. Among authors: snelder n. J Pharmacokinet Pharmacodyn. 2021 Feb;48(1):21-38. doi: 10.1007/s10928-020-09716-x. Epub 2020 Sep 14. J Pharmacokinet Pharmacodyn. 2021. PMID: 32929612 Free PMC article.
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis.
van den Berg P, Ruppert M, Mesic E, Snelder N, Seelmann A, Heinig R, Joseph A, Garmann D, Lippert J, Eissing T. van den Berg P, et al. Among authors: snelder n. Clin Pharmacokinet. 2022 Mar;61(3):439-450. doi: 10.1007/s40262-021-01082-2. Epub 2021 Nov 13. Clin Pharmacokinet. 2022. PMID: 34773606 Free PMC article. Clinical Trial.
Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria.
Goulooze SC, Snelder N, Seelmann A, Horvat-Broecker A, Brinker M, Joseph A, Garmann D, Lippert J, Eissing T. Goulooze SC, et al. Among authors: snelder n. Clin Pharmacokinet. 2022 Mar;61(3):451-462. doi: 10.1007/s40262-021-01083-1. Epub 2021 Nov 17. Clin Pharmacokinet. 2022. PMID: 34786651 Free PMC article. Clinical Trial.
PK/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients.
Willmann S, Marostica E, Snelder N, Solms A, Jensen M, Lobmeyer M, Lensing AWA, Bethune C, Morgan E, Yu RZ, Wang Y, Jung SW, Geary R, Bhanot S. Willmann S, et al. Among authors: snelder n. CPT Pharmacometrics Syst Pharmacol. 2021 Aug;10(8):890-901. doi: 10.1002/psp4.12663. Epub 2021 Jun 23. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34085768 Free PMC article.
26 results